Akari Therapeutics' Innovative Approach to Treating Rare Hematopoietic Stem Cell Transplant Complications| Rachelle Jacques, CEO, Akari Therapeutics PLC. 00:10:00

Share On Facebook Share On Twitter

Exploring the therapeutic potential of tick saliva proteins in treating severe hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), Akari Therapeutics pioneers a groundbreaking approach in biotech.

Recent Videos